

## Docetaxel 75 / Cisplatin 75, Non-Small Cell Lung Carcinoma

Protocol-ID: 144 V1.1 (Standard), DOCE75/CISP75, NSCLC

### Indication(s)

- Lung Carcinoma, Non-Small Cell; ICD-10 C34.-

### Protocol classification

- Classification: current standard
- Intensity: Standard dose
- Therapy mode: First line
- Therapy intention: palliative

### Cycles

Cycle length 21 days, recommended cycles: 6

### Risks

- Emetogenicity (MASCC/ESMO): high (>90%)
- Neutropenia: very high (>41%)
- Febrile Neutropenia: intermediate (10-20%)
- Thrombocytopenia below 50 000/ $\mu$ l: low (<10%)
- Anemia Hb below 8g/dl: moderate (6-15%)
- Cardiotoxicity: low (<10%)

### Therapy

#### Allergy prophylaxis: Docetaxel allergy prophylaxis, Dexamethasone

AP

Access: - none -

Docetaxel SmPC

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
-1	<b>Dexamethasone</b>	8 mg		p.o.		1-0-1-0

From day before therapy with Docetaxel, antihistamine therapy not provided for in summary of product characteristics.

#### Hydration: Hydration to Cisplatin (from 50 mg/m<sup>2</sup>)

HYD

Access: peripheral venous

Modified from Crona DJ et al 2017 and Hamroun A et al 2019.

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	<b>Balanced Crystalloid Solution</b>	3000 ml		i.v.	6 h	60 min before Docetaxel (d1)
Parallel to cisplatin and beyond. 20 mmol KCl and 4 mmol (10 ml) MgSO <sub>4</sub> added to 1000 ml balanced crystalloid solution						
1	<b>Potassium chloride</b>	60 mmol	none	i.v.	6 h	60 min before Docetaxel (d1)
1	<b>Magnesium sulfate</b>	12 mmol	none	i.v.	6 h	60 min before Docetaxel (d1)

**Antiemesis: Emetogenicity high, FOSAP, GRAN i.v., DEXA i.v.****AE**

Access: peripheral venous

DGHO 2016, DKG 2016, MASCC/ESMO 2016

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	<b>Fosaprepitant</b>	150 mg	NaCl 0.9% 150 ml	i.v.	20 min	30 min before Docetaxel (d1)
1	<b>Dexamethasone</b>	12 mg	NaCl 0.9% 50 ml	i.v.	5 min	30 min before Docetaxel (d1)
1	<b>Granisetron</b>	1 mg	NaCl 0.9% 50 ml	i.v.	5 min	15 min before Docetaxel (d1)
or other 5-HT3 receptor antagonist						
2-4	<b>Dexamethasone</b>	8 mg		p.o.		1-0-0-0
alternatively 4 mg 1-0-1						

**Antineoplastic therapy: CISP75/DOCE75****CTX**

Access: peripheral venous

Palliative therapy in advanced NSCLC

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	<b>Docetaxel</b>	75 mg/m <sup>2</sup> BSA	NaCl 0.9% 250 ml	i.v.	60 min	Sequence
Give docetaxel concurrently with hydration before cisplatin.						
1	<b>Cisplatin</b>	75 mg/m <sup>2</sup> BSA	NaCl 0.9% 500 ml	i.v.	60 min	Sequence

**Hematopoietic growth factors: FN risk 10-20%, G-CSF long-acting, pegylated****HW**

Access: - none -

Risk of febrile neutropenia (FN) 10-20% and 1 risk factor: age > 65 y, laboratory parameters (anemia, lymphocytopenia < 700/μl, hypalbuminemia, hyperbilirubinemia) previous chemotherapy, comorbidities, low performance status, advanced symptomatic tumor disease (DKG 2016)

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
2	<b>Pegfilgrastim</b>	6 mg		subc	Bolus	24 h after Cisplatin (d1)
Use at risk: FN 10-20% and 1 risk factor, other long-acting G-CSF possible.						

**Supportive therapy: Magnesium p.o.****SUP**

Access: - none -

For magnesium substitution in cisplatin therapies from 50mg/m<sup>2</sup>.

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1-3	<b>Magnesium</b>	150 mg		p.o.		1-0-1-0
For Cisplatin-containing therapies, 150 mg Magnesium corresponds to about 6.2 mmol.						

**Substance links**Links to substances are found [here](#).**Concomitant therapy supplements**

For highly emetogenic chemotherapy, additional olanzapine is recommended in the acute (day 1) and delayed phases (days 2-4) at a dosing of 5-10 mg per day (NCCN, ESMO, ASCO, Onkopedia; as of 6/24).

Dexamethasone for allergy prophylaxis is covered by dexamethasone for antiemesis on days 1 and 2.

**Notes**

in case of response 4-6 cycles, maximum 6

**Controls:**

- Blood count: 1x weekly

- Audiogram Ototoxicity of cisplatin
- Echocardiography, ECG Evaluation of cardiac pump function before cisplatin therapy.
- Day 1: Creatinine, glomerular filtration rate (GFR) Exclusion of renal insufficiency before cisplatin.
- Day 1: GOT, GPT, GGT, Bilirubin, AP, Cholinesterase Liver function prior to Docetaxel and Cisplatin administration, ongoing liver monitoring during therapy.
- Day 1,2: Na<sup>+</sup>, K<sup>+</sup>, Ca<sup>2+</sup>, Mg<sup>2+</sup> Exclusion of electrolyte imbalance during cisplatin and infusion therapy.
- Day 1-2: Weight

## Original author

Joan H. Schiller (2002)

## Origin

Eastern Cooperative Oncology Group

## References

- Schiller JH, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 Jan 10;346(2):92-8. doi: 10.1056/NEJMoa011954. PMID: 11784875. [[PMID](#)]
- Millward MJ, Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 1997 Feb;15(2):750-8. doi: 10.1200/JCO.1997.15.2.750. PMID: 9053501. [[PMID](#)]
- Fossella F, Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group J Clin Oncol 2003 Aug 15;21(16):3016-24. doi: 10.1200/JCO.2003.12.046. PMID: 12837811. [[PMID](#)]
- Novello S, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016 Sep;27(suppl 5):v1-v27. doi: 10.1093/annonc/mdw326. PMID: 27664245. [[PMID](#)]

## Recommendations

- 09/2021: [European Society for Medical Oncology](#)
- 02/2023: [National Comprehensive Cancer Network](#)

## Important notice

The copyrighted protocols are treatment recommendations. The information contained in this compilation on cytostatic drugs, concomitant medication and other therapeutic procedures, as well as dosage and application information, is continuously reviewed with all due care by the authors and editors involved. Nevertheless, the publishers and authors do not assume any liability for the correctness - also with regard to possible printing errors.

The protocols may not be changed in terms of content.

Diagnosis, indication for therapy and treatment of malignant diseases must be carried out in each individual case by the hematologist and oncologist on his or her own responsibility. The treating physician is obligated to this personal responsibility to weigh in each case before a diagnostic or therapeutic measure, indication, contraindications, dosage and application under consideration of the specialized information or other documents of the manufacturers. This applies in particular to rarely used preparations or preparations that are new to the market.



The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.